Last updated: 2026-09-14 12:27:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Jaguar Health, Inc. (JAGX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0,32, with a market capitalization of $1,62M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,29 to $77,63. This page covers its latest market performance, valuation, price trends and company information.
$1,62M | |
$0,31 | |
$79.605.524.250,00 | |
$0,29 | |
$0,31 | |
32,65K | |
206,84K | |
-- | |
$77,63 | |
$0,29 | |
-- | |
-- |
Jaguar Health, Inc. (JAGX) is trading at $0,32 in pre-market trading as of 2026-09-14 12:03:00, up 1,91% ($0,01) from the previous close of $0,31
Pre-market trading shows how investors are pricing JAGX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Jaguar Health, Inc. (JAGX) moved from $0,73 to $0,32, representing a decline of 56,16% ($0,41).
The stock traded between $0,29 and $0,77 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 820,63 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0,0%
JAGX is currently trading at $0,32, placing it 0,0% of the way from its 52-week low of $0,29 to its 52-week high of $77,63. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 47 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Jaguar Health, Inc. (JAGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.